The ozempic segment dominated the market in 2025 due to its effectiveness in controlling blood glucose levels in patients affected by type 2 diabetes
Patients and clinicians should interpret current evidence with appropriate caution given the drug's investigational status
Yes, the likelihood of side effects often goes up with higher doses
Identifying psychosocial interventions that improve both physical and mental health in patients with diabetes: a systematic review and meta-analysis
Chronic sleep deprivation disrupts appetite-regulating hormones
Mechanism of Action: Triple Receptor Agonist Retatrutide is a synthetic peptide that activates three key metabolic receptors: GLP-1 (Glucagon-Like Peptide-1) Enhances insulin secretion, suppresses appetite, delays gastric emptying GIP (Glucose-Dependent Insulinotropic Polypeptide) Boosts insulin response, improves insulin sensitivity, may support lipid metabolism Glucagon Receptor (GCGR) Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat This triple agonist profile delivers synergistic effects on glycemic control, fat loss, and metabolic health, making Retatrutide the most advanced incretin-based peptide in development
